September 2009
Worldwide Biotech;Sep2009, Vol. 21 Issue 9, p5
Trade Publication
The article reports on the agreement between Debiopharm Group and Mercury Therapeutics to develop and commercialize Debio 0930 as treatment for diabetes and metabolic diseases. The drug is a small molecule activator of adenosine monophosphate activated protein kinase (AMPK). The terms of the agreement are mentioned. Also given are brief company profiles of Debiopharm Group and Mercury Therapeutics Inc.


Related Articles

  • Debiopharm and Pharmaleads sign licensing agreement.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p17 

    The article reports on an exclusive license agreement signed by Debiopharm Group for the development, registration and commercialization of a small molecule called Debio 0827 or PL37 in the U.S. The agreement allows Debiopharm to make an up-front payment to Pharmaleads. It is revealed that Debio...

  • Licensing Update.  // PharmaWatch: Biotechnology;Sep2009, Vol. 8 Issue 9, p23 

    The article offers update related to the licensing agreements of several research institutes and biopharmaceutical companies. Tibotec Pharmaceuticals Ltd. entered to a licensing and partnership agreement with Gilead Sciences Inc. for the development and commercialization of an antiretroviral...

  • Other News To Note.  // BioWorld Today;10/25/2013, Vol. 24 Issue 206, p2 

    This section offers news briefs on the biopharmaceutical industries. The cyclic pyranopterin monophosphate (ALXN1101) of Alexion Pharma International Sarl was given breakthrough therapy designation by the U.S. Food and Drug Administration. A collaboration agreement was reached between Atheris...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/17/2008, Vol. 19 Issue 224, p2 

    This section offers news briefs related to the biotechnology industry. Debiopharm Group announced that its new drug application for the formulation of Trelstar was accepted for filing by the U.S. Food and Drug Administration. ISTA Pharmaceuticals Inc. reported that it filed a new drug...

  • OTHER NEWS TO NOTE.  // BioWorld International;7/29/2009, Vol. 14 Issue 30, p2 

    This section offers news briefs concerning the biotechnology sector as of July 2009. An agreement was signed by BioAlliance Pharma SA to co-promote the antidepressant Seroplex by H. Lundbeck A/S. Eisai Co. Ltd. has exercised its option to license the drug-eluting DC Bead and Precision Bead...

  • Debiopharm and Moffitt sign licensing agreement for anticancer drug.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p19 

    The article reports on the agreement signed between Swiss biopharmaceutical group of companies Debiopharm Group and Moffitt Cancer Center, a non-profit corporation, in the U.S. An exclusive licensing deal is disclosed between the two companies for the development and commercialization of Debio...

  • DEBIOPHARM TO CONTINUE BRAINZ STUDY WITH DEBIO 9902 SR.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p6 

    The article reports that global independent biopharmaceutical company Debiopharm Group in Lausanne, Switzerland, has received a recommendation to continue its Phase II BRAINz study with Debio 9902 sustained release (SR) for the treatment of Alzheimer's disease without modification. According to...

  • Debiopharm offers encouraging data for Alzheimer's treatment.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p7 

    The article reports that the Swiss biopharmaceutical company Debiopharm Group has revealed the final results of two studies for its Alzheimer's disease (AD) treatment. Findings of the trials suggest that Debio 9902 SR implants are safe and effective in the treatment of moderate AD. Principal...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/18/2008, Vol. 19 Issue 225, p2 

    This section offers world news briefs. The Boston, Massachusetts-based subsidiary of Advanced Proteome Therapeutics Corp. of Vancouver, British Columbia develops kinetic labeling libraries to screen protein targets for binding sites. Altus Pharmaceuticals Inc. of Waltham, Massachusetts plans to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics